Table 3.
OviTex ventral hernia published studies.
| Parker, 2021 [22] | Ankney, 2021 [24] | Sivaraj, 2022 [23 | |||||
|---|---|---|---|---|---|---|---|
| Total Pts | 50 OviTex | 50 Synthetic | 259 OviTex | 36 OviTex | 51 NC-PADM1 | 17 C-PADM2 | 37 BADM3 |
| Follow-Up | 12 Months | 12 Months | 1–59 Months | 28.6 median (±12.1) | 34.6 median (±15.2) | 58.4 median (±19.4) | 37.5 median (±17.5) |
| Patient Demographics | CDC II+ (70%) | CDC I (94%) | -- | CDC I-II (89%) | CDC I-II (86.0%) | CDC I-II (94.2%) | CDC I-II (91.4%) |
| mVHWG |
II (32%) III (68%) |
II (94%) III (6%) |
-- | I (33.4%) | I (17%) | I (17.6%) | I (40.0%) |
| II (58.3%) | II (78.7%) | II (70.6%) | II (51.4%%) | ||||
| III (8.3%) | III (4.3%) | III (11.8%) | III (8.6%) | ||||
| Incidence of SSO | 36% | 22% | 1.5%b | 16.7%a | 47.1%a | 52.9%a | 43.2%a |
| Incidence of SSI | -- | – | 0.8%b | 2.78% | 12.5% | 11.8% | 5.41% |
| Recurrence Rate | 6% | 12% | 0.8%b | 2.78% | 13.7% | 29.4% | 24.3% |
a
Overall complications including SSI; 1 noncross-linked porcine acellular dermal matrix; 2 cross-linked porcine dermal biologic mesh; 3 fetal bovine acellular dermal matrix.
b
SSO rate calculated (4/259), SSI rate calculated (2/259), recurrence rate calculated (2/259)